[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrectomy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,44,78,103,131,152,175,201,224,247,292,312,340],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100578406","intravenous-versus-perineural-ondansetron-for-laparoscopic-sleeve-gastrectomy-100578406",false,"NCT06810882","Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy","Intravenous Versus Perineural Ondansetron as an Adjuvant in Autonomic Neural Blockade for Laparoscopic Sleeve Gastrectomy: A Two-Center, Randomized, Double-Blind, Non-inferiority Trial","Inclusion Criteria:\n\n* Patients of either sex\n* American Society Anesthesiologists physical (ASA) status II-III\n* age between 18-65 years old\n* Body mass index (BMI) \\>35 kg\u002Fm2 with comorbidity or \\> 40 kg\u002Fm2 -- undergoing laparoscopic sleeve gastrectomy with intraoperative surgeon performed laparoscopic paragastric autonomic neural blockade..\n\nExclusion Criteria:\n\n* Allergy to experimental drugs.\n* Known to have long QT, previous history of postoperative nausea and vomiting\n* Abuse of alcohol, analgesia, or sedative antidepressant drugs\n* Chronic pain disorders\n* History of previous upper gastrointestinal system surgery, those with surgery-related complications during or after surgery.\n* Liver or kidney failure\n* Performance of concomitant procedures in addition to laparoscopic sleeve gastrectomy\n* Anesthetic complications that may alter the postoperative management protocol.","ALL","18 Years","65 Years",{"count":20,"type":21},482,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective randomized non-inferiority study will be conducted to compare the analgesic anti-emetic effects of intravenous ondansetron versus perineural ondansetron in patients undergoing laparoscopic sleeve gastrectomy.",[27,28,29],"Ondansetron","Laparoscopic","Gastrectomy",[27,28,29],"RECRUITING","2026-05-13",{"date":34,"type":35},"2026-05-15","ACTUAL",{"date":37,"type":35},"2025-02-16",{"date":39,"type":21},"2027-02-17",{"name":41,"class":42},"Tanta University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100640765","phase-2-anakinra-for-the-treatment-of-postprandial-hypoglycemia-in-a-patient-with-total-gastrectomy-and-end-stage-renal-disease-100640765","NCT07580079","Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease","Anakinra for the Treatment of Recurrent Postprandial Hypoglycemia After Total Gastrectomy in a Patient With End-Stage Renal Disease","AnPHy-ReD","This is an N-of-1 Trial, tailored-designed to a single participant.\n\n* total gastrectomy\n* severe episodes of postprandial hypoglycaemia after total gastrectomy","MALE",{"count":43,"type":21},[55],"PHASE2","Post-meal low blood sugar (postprandial hypoglycemia) is a common problem after certain stomach surgeries like gastric bypass or stomach removal. It usually happens 1 to 3 hours after eating and can cause symptoms such as tiredness, hunger, sweating, dizziness, trouble speaking, or even fainting. Right now, there is no approved medication for this condition-only a careful diet reduced in sugars and refined carbohydrates can sometimes help reduce symptoms.\n\nThe AnPHy-ReD study is a personalized research study, designed for just one patient. This patient is a 52-year-old man who has been struggling with severe post-meal low blood sugar ever since his stomach was removed due to tumor in 2017. He also has end-stage kidney disease and needs dialysis three times a week.\n\nThe study is being conducted at the Cantonal Hospital of Olten in Switzerland and lasts 10 weeks, including 24 study visits. Most of these visits will happen during the patient's regular dialysis sessions. For 6 weeks, the patient will take either the drug Anakinra or a placebo (a substance with no active ingredient), in a randomly chosen order. Neither the patient nor the doctors will know which one he is taking at any given time.\n\nDuring the study, the medical team will perform various tests, including physical check-ups and blood samples to look at sugar levels, various hormone levels and inflammation in the body. The patient will also wear a continuous glucose monitor (CGM) to track his blood sugar levels 24\u002F7. In addition, he will do several mixed meal tests-this means drinking a shake containing fats, proteins, and sugars during a study appointment to see in real time how his body processes food, with doctors measuring changes in blood sugar, hormone and inflammation markers over time. During the study duration any side effects or symptoms will be closely monitored.\n\nAt the end of the study, the team will compare the results between the times the patient took Anakinra and the times he took the placebo. This will help find out if Anakinra can reduce sharp drops in blood sugar after meals and improve his overall condition.",[58,59,29,60,61,62],"Postprandial Hypoglycemia","End-stage Renal Disease (ESRD)","Glucose Metabolism Disorders","Inflammation","Gastric Bypass Surgery",[58,64,65,66,67,61],"End-Stage Renal Disease","Anakinra","Gastric Bypass","IL-1 receptor antagonist","NOT_YET_RECRUITING","2026-05-05",{"date":71,"type":35},"2026-05-12",{"date":73,"type":21},"2026-07",{"date":75,"type":21},"2026-12",{"name":77,"class":42},"Marc Donath",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":43},"100632726","the-ugira-international-registry-for-ramig-for-gastric-cancer-100632726","NCT07517432","The UGIRA International Registry for RAMIG for Gastric Cancer","The UGIRA International Registry for Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) for Gastric Cancer","Inclusion Criteria:\n\n* All gastric cancer patients undergoing RAMIG in a center\n\nExclusion Criteria:\n\n* No",{"count":86,"type":21},200,"10 Years","OBSERVATIONAL","Minimally invasive gastrectomy (MIG) has gained in popularity, since it is feasible, safe and oncologically comparable to open gastrectomy, while morbidity and duration of hospitalization are reduced, quality of life is increased, and conversion rate is low.\n\nHowever, several challenges are faced during MIG, such as impaired depth perception and limited range of motion of instrument tips. Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) can potentially overcome these challenges, while providing comparable results regarding safety, technical feasibility, morbidity and oncological effectiveness. However, the techniques and outcomes of RAMIG vary in literature, which can partly be explained by lack of uniform definitions of postoperative outcomes that would allow international comparison. Furthermore, RAMIG is technically demanding and therefore associated with a learning curve.\n\nTo facilitate safe and effective implementation of RAMIG worldwide, the learning curve for RAMIG-procedures must be evaluated in detail. A prospective international registry with uniform data collection regarding surgical techniques and postoperative outcomes can provide a platform for multicontinental studies and the monitoring of surgical quality for surgeons who are implementing RAMIG in their center. Therefore, the aim of this study proposal is to expand the Upper Gastrointestinal International Robotic Association (UGIRA) collaboration by creating the UGIRA International Registry for RAMIG. The UGIRA network extends worldwide with members in Europe, Asia, North-America and South-America, therefore representing large-scale practice of RAMIG. The initial specific aims of the registry are to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG.\n\nData for this registry is collected prospectively and retrospectively.",[91,29],"Gastric Cancer (Diagnosis)",[93,29],"gastric cancer","2026-04-01",{"date":96,"type":35},"2026-04-08",{"date":98,"type":35},"2021-04-01",{"date":100,"type":21},"2031-03-31",{"name":102,"class":42},"Chinese University of Hong Kong",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100520582","phase-3-the-pancreatic-enzymes-after-gastrectomy-trial-100520582","NCT06058442","The Pancreatic Enzymes After Gastrectomy Trial","Inclusion Criteria:\n\n1. Gastrectomy (total and partial); at least \\> 50 % of the stomach must be resected\n2. Age 18 or older\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Indication for pancreas enzyme therapy\n2. Gastrectomy with palliative intention\n3. UICC (Union for International Cancer Control) Stage IV gastric malignancy\n4. Malnutrition of other aetiology\n5. Life expectancy \\\u003C 12 months\n6. Known lactose intolerance\n7. Known hereditary galactose intolerance\n8. Patients on alpha-glucosidase inhibitors (AGIs)\n9. Acute pancreatitis\n10. Acute episode of chronic pancreatitis\n11. Known hypersensitivity to moulds (mould allergy) or any other ingredient of NORTASE®\n12. Participation in competing interventional trials may be allowed under circumstances\n13. Patients under legal supervision or guardianship\n14. Patients who are dependent on the investigator or the medical staff of the trial team or the coordinating investigator or the sponsor\n15. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial\n16. Pregnant or nursing women\n17. Suspected lack of compliance\n18. Patients who were already enrolled in the trial",{"count":110,"type":21},188,[112],"PHASE3","This trial evaluates the effects (e.g. on quality of life, weight) of NORTASE® compared to standard care of patients who have undergone gastrectomy.",[29],[116,117,118,119,120],"enzyme supplementation","lipase","elastase","gastrointestinal","quality of life","2026-01-19",{"date":123,"type":35},"2026-01-22",{"date":125,"type":35},"2024-01-24",{"date":127,"type":21},"2027-06",{"name":129,"class":42},"University of Leipzig",9,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":43},"100618318","phase-2-efficacy-and-safety-of-anrikefon-injection-for-the-treatment-of-postoperative-pain-in-patients-undergoing-totally-laparoscopic-radical-distal-gastrectomy-100618318","NCT07330063","Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy","Inclusion Criteria:\n\n* Aged between 18 and 70 years old (inclusive).\n* American Society of Anesthesiologists (ASA) physical status classification Class I-III.\n* Body Mass Index (BMI) ranging from 18 kg\u002Fm² to 30 kg\u002Fm² (inclusive).\n* Patients scheduled for elective total laparoscopic distal gastrectomy for gastric cancer under general anesthesia, with surgical duration \\\u003C 5 hours.\n* Surgical incision length \\\u003C 8 cm.\n* Voluntarily agree to participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients undergoing emergency surgery or suffering from trauma.\n* Patients who undergo conversion to open surgery or laparoscopically assisted distal gastrectomy for gastric cancer during the operation.\n* Patients who refuse to receive Patient-Controlled Intravenous Analgesia (PCIA).\n* Patients with a history of prior abdominal surgery.\n* Patients expected to require prolonged endotracheal intubation after surgery.","70 Years",{"count":139,"type":21},114,[55],"Anruikefen is a peripherally highly selective kappa receptor agonist that does not easily cross the blood-brain barrier, resulting in a low incidence of central adverse reactions such as respiratory depression, sedation, and addiction. As a Class 1 new drug, it was approved for marketing in China on May 13, 2025, and is indicated for the treatment of postoperative pain following abdominal surgery. Results from two Phase Ⅲ randomized controlled trials (RCTs) of Anruikefen have demonstrated its significant analgesic efficacy, with the incidence of postoperative nausea and vomiting (PONV) being 50% significantly lower than that in the placebo group, which confirms the favorable safety profile of Anruikefen Injection.\n\nTherefore, this investigator-initiated trial (IIT) is designed to further verify the efficacy and safety of Anruikefen in patients undergoing total laparoscopic distal gastrectomy for gastric cancer.",[29],"2025-12-29",{"date":145,"type":35},"2026-01-09",{"date":147,"type":21},"2025-12-22",{"date":149,"type":21},"2026-06-30",{"name":151,"class":42},"Tianjin Medical University Cancer Institute and Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":43},"100591618","how-epigenetic-changes-in-hmlh1-connect-lab-research-with-diagnosis-in-gastric-cancer-100591618","NCT06982768","How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer","Epigenetic Mechanisms Bridging Research and Clinical Examination in hMLH1 Hypermethylated Gastric Cancer","EMBRACE-hGC","Inclusion Criteria:\n\n* Patients who underwent elective gastrectomy for Stage I-IV gastric cancer.\n* Surgery performed at the General Surgery Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS.\n* Procedures conducted between January 2017 and August 2023.\n* Only patients who have already undergone immunohistochemistry evaluation for expression of the components of the MMR complex (MLH1, PMS2, MSH2, and MSH6).\n\nExclusion Criteria:\n\n\\- Patients with missing immunohistochemistry evaluation for the expression of the components of the MMR complex (MLH1, PMS2, MSH2, and MSH6).",{"count":161,"type":21},245,"DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have been developed and have demonstrated an association with mortality and, in some cases, with cancer incidence. Accordingly, CpG promoter hypermethylation is a well-known mechanism of gene inactivation in carcinogenesis.\n\nGastric cancer has been classified in different molecular phenotypes based on genetic and epigenetic characteristics. One of these subtypes is characterized by a high grade of microsatellite instability (MSI-H). In gastric cancer, the MSI-H status is mostly caused by methylation of the hMLH1 gene promoter (between 71% and 78%), that is also considered the representative of a gastric-specific CpG island methylation pattern (CIMP). Gastric cancer with hMLH1 hypermethylation is frequently expressed in the MSI-H phenotype but also reported in the MSI-L type. Hypermethylation has been associated with advanced age, dietary habits, smoking and alcohol consumption. Moreover, other studies on GI cancer (colorectal, rectal and gastric) have associated hMLH1 hypermethylation with decreased levels of folate, vitamin C and niacin. Last, increased oxidative stress has been proposed as one of the possible initiators of cancer development and progression through epigenetic mechanism as hypermethylation. From a clinical standpoint, MSI-H gastric cancers have been associated with increased resistance to standard chemotherapy and increased immunogenicity, representing a hypothetic ideal target to immunotherapy, that has documented clinical efficacy for this subtype. However, some authors have suggested that MSI-H GCs without hMLH1 hypermethylation and GCs with hMLH1 hypermethylation could be different in terms of clinicopathologic characteristics and biological behavior. In addition, the specific role of hMLH1 hypermethylation in resistance to standard chemotherapy is unknown, as well as its potential adjunctive role in the chemoresistance of hypermethylated - but MSI-L - tumors.\n\nIdentifying risk factors for hMLH1 hypermethylated GC could have relevant implications in terms of disease prevention and even reversal of the hypermethylation mechanisms through natural as well as synthetic compounds. It could also identify a predictive tool to better stratify patients for expected sensitivity to specific chemotherapy (or biological therapy) regimens. Therefore, this preliminary study aims to determine if the development of hMLH1-methylated GC is associated with specific clinicopathologic characteristics and environmental habits. It also aims to report on the biological behavior of these tumors, as well as on their chemosensitivity to platin-based chemotherapy regimens.",[164,29,165,166],"Gastrectomy for Gastric Cancer","MLH1 Gene Mutation","Gastric Cancer",{"date":168,"type":35},"2026-01-02",{"date":170,"type":35},"2024-09-01",{"date":172,"type":21},"2026-04-30",{"name":174,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100616843","gastric-ultrasound-in-patients-who-have-undergone-bariatric-surgery-100616843","NCT07310875","Gastric Ultrasound in Patients Who Have Undergone Bariatric Surgery","Inclusion Criteria:\n\n* 18-85 years old\n* scheduled to undergo bariatric surgery\n* no prior abdominal surgery\n\nExclusion Criteria:\n\n* ASA physical status \\> 3\n* Urgent or emergent surgery\n* Patient refusal or inability to consent\n* Prior abdominal surgery","85 Years",{"count":183,"type":21},10,[24],"This is a nonrandomized prospective study. The purpose is to describe how to image the stomachs of patients after the patients have had bariatric surgery. Participants will have the stomachs imaged while undergoing general anesthesia for a bariatric procedure pre-operatively and post-operatively using point-of-care ultrasound (POCUS). The pre-operative imaging will be done post-intubation and the post-operative imaging will be done pre-extubation. There are minimal risks to gastric POCUS. Risks typically include discomfort to the patient, which will be avoided as the patient will be under general anesthesia at the time of imaging.",[187,188,29],"Obesity","Weight Loss",[190,191],"Point of Care Ultrasound","Sleeve gastrectomy","2025-12-16",{"date":194,"type":35},"2025-12-30",{"date":196,"type":21},"2025-12",{"date":198,"type":21},"2026-12-30",{"name":200,"class":42},"Icahn School of Medicine at Mount Sinai",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100602000","feasibility-and-safety-of-laparoscopic-purse-string-suture-clamp-and-multi-functional-seal-cap-for-totally-laparoscopic-radical-total-gastrectomy-100602000","NCT07117812","Feasibility and Safety of Laparoscopic Purse-string Suture Clamp and Multi-functional Seal Cap for Totally Laparoscopic Radical Total Gastrectomy","Inclusion Criteria:\n\n* Age 18-80 years, regardless of gender; Histologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma. For GEJ cancer, only Siewert type III and type II (without requiring thoracotomy) are eligible (applicable to multiple primary cancers); Preoperative assessment by a gastrointestinal surgeon and imaging specialist confirming cStage I-III disease with eligibility for curative-intent R0 resection. Patient consents to surgery and is deemed surgically fit by the surgeon; Anticipated R0 resection achievable via total gastrectomy with D1+\u002FD2 lymphadenectomy; Expected survival ≥6 months; ECOG Performance Status (PS) score (see Appendix 2) of 0 or 1; Adequate major organ function; Body weight ≥40 kg or BMI \\>18.5 and \\\u003C30 kg\u002Fm²; No prior chemotherapy, radiotherapy, targeted therapy, or immunotherapy; Patient has read and fully understood the informed consent form and voluntarily signed it\n\nExclusion Criteria:\n\n* History of other active malignancies within the past 5 years or concurrent malignancies (except cured localized tumors such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate\u002Fcervix\u002Fbreast, Stage I lung\u002Fcolorectal cancer, etc.).\n\nPrevious upper abdominal surgery (excluding laparoscopic cholecystectomy). History of gastrectomy, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD).\n\nRequirement for concurrent surgery for other diseases. Emergency surgery due to gastric cancer complications (bleeding, obstruction, or perforation).\n\nPlanned or prior organ\u002Fbone marrow transplantation. Blood transfusion within 2 weeks before surgery, bleeding history, or Grade ≥3 hemorrhage (CTCAE v4.0) within 4 weeks.\n\nCoagulopathy (INR \\>1.5 without anticoagulants) or use of anticoagulants (warfarin\u002Fheparin). Prophylactic low-dose warfarin (≤1 mg\u002Fday) or aspirin (≤100 mg\u002Fday) is permitted if INR ≤1.5.\n\nArterial\u002Fvenous thrombosis within 6 months (e.g., stroke, DVT, pulmonary embolism), excluding catheter-related thrombosis from prior chemotherapy.\n\nMyocardial infarction within 6 months or uncontrolled arrhythmia (QTc ≥450 ms \\[men\\]\u002F≥470 ms \\[women\\] by Fridericia's formula).\n\nNYHA Class III-IV heart failure or LVEF \\\u003C50%. Ventilatory dysfunction (FEV1 \\\u003C50% predicted). Urinary protein ≥++ or 24-hour urine protein \\>1.0 g. Clinically significant pleural\u002Fperitoneal effusion requiring intervention. HIV infection. Active tuberculosis. Non-healing wounds or incomplete fracture healing. Active\u002Fsuspected autoimmune disease (stable cases without immunosuppressants allowed).\n\nSevere autoimmune diseases (e.g., SLE, IBD), chronic diarrhea disorders, or active HBV\u002FHCV (HBV DNA \\\u003C500 copies\u002FmL permitted).\n\nSystemic corticosteroids (\\>10 mg\u002Fday prednisone equivalent) within 14 days (topical\u002Finhaled steroids or physiologic replacement doses allowed).\n\nActive infection requiring systemic antibiotics within 14 days (prophylactic antibiotics permitted).\n\nLive vaccines within 28 days (inactivated flu vaccines allowed). Concurrent participation in another surgical trial. Alcohol\u002Fdrug abuse history (abstinent patients eligible). Non-compliance or incomplete data affecting safety\u002Fefficacy assessments. Pregnancy\u002Flactation. Other conditions deemed high-risk by investigators. Investigator-determined ineligibility.","80 Years",{"count":209,"type":21},50,[24],"Currently, there are three main methods for endoscopic esophagojejunostomy: circular, linear, and hand-sewn anastomosis, but no universally accepted optimal approach has been established.\n\nHand-sewn anastomosis relies on advanced endoscopic suturing skills, making it technically demanding and only performed in a limited number of hospitals.\n\nLinear anastomosis is simple to perform and the most widely used in clinical practice. However, it requires resection of a longer segment of the distal esophagus and may struggle to ensure adequate margins for high-positioned tumors or unclear resection boundaries.\n\nCircular anastomosis is a classic method. Its end-to-side approach preserves more esophageal length, making it suitable for high-positioned tumors without the need to close a common opening. Various techniques (e.g., the reverse-puncture method and the Orvil™ transoral anvil technique) have been reported. However, due to challenges such as purse-string suturing, complex anvil placement, and restricted stapler maneuverability, widespread adoption remains difficult.\n\nProf. Du Jianjun's team innovatively employed endoscopic purse-string forceps and a multifunctional sealing ring to achieve circular anastomosis, demonstrating preliminary technical advantages. This study further explores its feasibility and short-term outcomes in totally endoscopic total gastrectomy.",[213,29,214,28],"Gastric Cancer (GC)","Anastomosis, Roux-en-Y","2025-08-12",{"date":217,"type":35},"2025-08-15",{"date":219,"type":21},"2025-09-01",{"date":221,"type":21},"2027-09-01",{"name":223,"class":42},"The First Affiliated Hospital with Nanjing Medical University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":43},"100385189","reduced-port-laparoscopic-gastrectomy-for-gastric-cancer-100385189","NCT04295473","Reduced Port Laparoscopic Gastrectomy for Gastric Cancer","Comparison the Short and Long-term Outcome of Patients With Gastric Cancer Who Underwent Reduced Port Laparoscopic Gastrectomy With Patients Underwent Traditional Laparoscopic Gastrectomy","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages.\n2. Eastern Cooperative Oncology Group performance status of 0 or 1.\n3. Adequate organ function.\n\nExclusion Criteria:\n\n1. Patients had distant metastasis.\n2. oesophageal invasion of more than 3 cm.\n3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma.\n4. Previous chemotherapy or radiation therapy for any other malignancies.","90 Years",{"count":233,"type":21},160,[24],"Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated. The investigators sought to compare the short and long-term outcome of patients with gastric cancer who underwent reduced port gastrectomy with patients underwent traditional laparoscopic gastrectomy",[28,29],"2025-05-16",{"date":239,"type":35},"2025-05-21",{"date":241,"type":35},"2020-03-02",{"date":243,"type":21},"2027-03-01",{"name":245,"class":246},"Nanchong Central Hospital","OTHER_GOV",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":207,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":273,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.",{"count":256,"type":21},150,[55,112],"The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[166,260,261,262,263,264,265,266,267,268,269,270,29,164,271,272],"Stomach Cancer","GastroEsophageal Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Gastric Neoplasm","Stomach Neoplasm","Gastrointestinal Cancer","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma","Chemotherapy","Gastric Resection","Gastric (Cardia, Body) Cancer",[274,275,276,29,277,278,279,280,281],"Total neoadjuvant chemotherapy","FLOT","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","Gastric cancer","2025-04-30",{"date":284,"type":35},"2025-05-06",{"date":286,"type":35},"2025-03-25",{"date":288,"type":21},"2032-12-31",{"name":290,"class":42},"Ukrainian Society of Clinical Oncology",2,{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":43},"100547097","the-impact-of-laparotomy-and-analgesia-methods-on-diaphragm-100547097","NCT06403540","The Impact of Laparotomy and Analgesia Methods on Diaphragm","The Impact of Laparotomy and Analgesia Methods on Postoperative Diaphragm Muscle Contraction in Major Abdominal Surgeries.","Inclusion Criteria:\n\n* over 18 years,\n* major abdominal surgery cases\n\nExclusion Criteria:\n\n* body mass index (BMI) \\>35 kg\u002Fm2\n* illiteracy,\n* communication issues,\n* neuromuscular disorders,\n* Advanced chronic respiratory disease,\n* Previous abdominal or thoracic surgery",{"count":300,"type":21},90,"Major abdominal surgeries are traditionally performed via laparotomy. Analgesia is routinely administered during the postoperative period. The goal is to investigate the effects of laparotomy and analgesia methods on diaphragm function.",[303,29],"Colorectal Neoplasms","2025-04-29",{"date":282,"type":35},{"date":307,"type":35},"2025-01-30",{"date":309,"type":21},"2025-08-01",{"name":311,"class":42},"Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":43},"100423818","the-effect-of-intensive-dietary-education-on-nutritional-status-after-gastrectomysing-100423818","NCT04798820","The Effect of Intensive Dietary Education on Nutritional Status After Gastrectomy(SING)","A Randomized Clinical Trial of Simplified Dietary Education Versus Intensive Dietary Education on Nutritional Status After Gastrectomy","SING","Inclusion Criteria:\n\n* histologically proven primary gastric adenocarcinoma,\n* T1N0, T1N1, T2N0, which are assessed by computed tomography (CT) scan (AJCC 8th classification) and intraoperative surgical staging\n* location of primary tumor; antrum, or angle, , lower body or mid body of the stomach\n* No evidence of other distant metastasis,\n* age ≥ 20 year old, ≤ 75 year old\n* no prior or posterior treatment of chemotherapy or radiation therapy against any other malignancies\n* adequate organ functions defined as indicated below:\n\n  1. WBC count: 3000\u002Fmm3 \\~12,000\u002Fmm3,\n  2. \\> serum Hemoglobin 8.0 g\u002FdL\n  3. \\> serum Platelet 100 000\u002Fmm3,\n  4. \\\u003C serum AST 100 IU\u002FL,\n  5. \\\u003Cserum ALT 100 IU\u002FL,\n  6. \\\u003C Total Bilirubin 2.0 mg\u002FdL,\n* written signed informed consent\n\nExclusion Criteria:\n\n* active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer),\n* gastric remnant cancer\n* ≥T3, T4 in surgical staging before resection\n* N2 or more (number of metastatic lymph nodes ≥3) in CT scan\n* histologically rare variants in World Health Organization (WHO) Classification such as Adenosquamous, Hepatoid, Squamous cell, Undifferentiated, neuroendocrine carcinoma and others\n* pregnant or breast-feeding women,\n* mental disorder(diagnosed with mental disorder on medical record),\n* unstable angina or myocardial infarction within 6 months of the trial,\n* unstable hypertension,\n* diabetes mellitus on insulin,\n* severe respiratory disease requiring continuous oxygen therapy,\n* previous upper abdominal surgery except laparoscopic cholecystectomy,\n* surgical complication","20 Years","75 Years",{"count":323,"type":21},358,[24],"Radical gastrectomy has been known as the most effective treatment of curable gastric cancer.However, there is a high risk of malnutrition and weight loss after a gastrectomy which may be attributed to inadequate oral consumption, malabsorption and loss of the reservoir function of the stomach.Weight loss has been regarded as an independent risk factor for postoperative mortality and morbidity and It is also closely associated with a quality of life after surgery. No specific surgical technique has been proved to be effective in reducing postoperative weight loss and it seems like that dietary education and consultation is the best way to minimize weight loss in gastrectomy patients in clinical setting. In this regard, the investigators performed a retrospective pilot study to identify the effect of routinely performed (simplified) dietary education on nutritional status after gastrectomy, but it revealed that the effect of simplified dietary education on weight loss was not clear and the result implies that more intensive dietary education may be necessary after gastrectomy. The aim of this randomized controlled trial (RCT) is to elucidate the effect of intensive dietary education on nutritional status after gastrectomy in comparison with simplified dietary education.",[166,29],[93,328,329,330],"gastrectomy","dietary education","nutritional status","2024-07-11",{"date":333,"type":35},"2024-07-15",{"date":335,"type":35},"2021-03-09",{"date":337,"type":21},"2025-10",{"name":339,"class":42},"Samsung Medical Center",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":320,"maxAge":321,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100520873","protocol-for-comparing-the-efficacy-of-three-reconstruction-methods-of-the-digestive-tract-after-proximal-gastrectomy-100520873","NCT06062225","Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy","Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract (Kamikawa Versus Single-Tract Jejunal Interposition Versus SOFY Reconstruction) After Proximal Gastrectomy","Inclusion Criteria:\n\n* Age between 20-75 years old, male or female;\n* Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1\u002F3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) (14) according to the eighth edition of the AJCC (15);\n* No distant metastasis observed on preoperative chest radiograph, abdominal ultrasound or upper abdominal CT;\n* ASA grade 1-3;\n* Patients without contraindications to surgery;\n* Patients and their families voluntarily signing the informed consent form and participating in the study;\n\nExclusion Criteria:\n\n* Patients diagnosed with primary tumors or distant metastasis;\n* Patients whose tumor is located in the greater curvature side of the stomach;\n* Patients with coagulation dysfunction which could not be corrected;\n* Patients who were diagnosed with viral hepatitis and cirrhosis;\n* Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin;\n* Patients with organ failure such as heart, lung, liver, brain, kidney failure;\n* Patients with ascites or cachexia preoperatively in poor general conditions;\n* Patients diagnosed with immunodeficiency, immunosuppression or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).\n* Patients refusing to sign the informed consent of the study;",{"count":348,"type":21},180,[24],"The efficacy of three different reconstruction methods after proximal gastrectomy will be investigated in this study through a prospective, multicenter, randomized controlled trial.",[352,29,353,354,355],"Proximal Gastric Adenocarcinoma","Anastomosis","Reflux Esophagitis","Postoperative Complications","2023-10-03",{"date":358,"type":35},"2023-10-05",{"date":360,"type":21},"2023-10",{"date":362,"type":21},"2026-10",{"name":364,"class":42},"Changzhi People's Hospital Affiliated to Changzhi Medical College"]